Functional Convalescent Plasma Antibodies and Pre-infusion Titers Shape the Early Severe COVID-19 Immune Response

Overview

Journal Nat Commun

Specialty Biology

Date 2021 Nov 26

PMID 34824251

Citations 25

Authors

Jonathan D Herman

Chuangqi Wang

Carolin Loos

Hyunah Yoon

Johanna Rivera

M Eugenia Dieterle

Denise Haslwanter

Rohit K Jangra

Robert H Bortz 3rd

Katharine J Bar

Boris Julg

Kartik Chandran

Douglas Lauffenburger

Liise-Anne Pirofski

Galit Alter

Affiliations

Soon will be listed here.

Abstract

Transfer of convalescent plasma (CP) had been proposed early during the SARS-CoV-2 pandemic as an accessible therapy, yet trial results worldwide have been mixed, potentially due to the heterogeneous nature of CP. Here we perform deep profiling of SARS-CoV-2-specific antibody titer, Fc-receptor binding, and Fc-mediated functional assays in CP units, as well as in plasma from hospitalized COVID-19 patients before and after CP administration. The profiling results show that, although all recipients exhibit expanded SARS-CoV-2-specific humoral immune responses, CP units contain more functional antibodies than recipient plasma. Meanwhile, CP functional profiles influence the evolution of recipient humoral immunity in conjuncture with the recipient's pre-existing SARS-CoV2-specific antibody titers: CP-derived SARS-CoV-2 nucleocapsid-specific antibody functions are associated with muted humoral immune evolution in patients with high titer anti-spike IgG. Our data thus provide insights into the unexpected impact of CP-derived functional anti-spike and anti-nucleocapsid antibodies on the evolution of SARS-CoV-2-specific response following severe infection.

Citing Articles

Retrospective Analysis of Coronavirus SARS-CoV-2 Antibody Levels in COVID-19 Convalescent Plasma From Blood Donors.

He J, Zhang Y, Dong J, Zhang W, Zhu F Can J Infect Dis Med Microbiol. 2024; 2024:4366502.

PMID: 39668998 PMC: 11637619. DOI: 10.1155/cjid/4366502.

Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation.

Park H, Yu C, Pirofski L, Yoon H, Wu D, Li Y BMC Infect Dis. 2024; 24(1):639.

PMID: 38926676 PMC: 11201301. DOI: 10.1186/s12879-024-09529-0.

Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis.

Franchini M, Focosi D, Cruciani M, Joyner M, Pirofski L, Senefeld J Diseases. 2024; 12(3).

PMID: 38534965 PMC: 10969279. DOI: 10.3390/diseases12030041.

Control of complement-induced inflammatory responses to SARS-CoV-2 infection by anti-SARS-CoV-2 antibodies.

Bermejo-Jambrina M, van der Donk L, van Hamme J, Wilflingseder D, de Bree G, Prins M EMBO J. 2024; 43(7):1135-1163.

PMID: 38418557 PMC: 10987522. DOI: 10.1038/s44318-024-00061-0.

Design of VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1): A double-blind, randomized placebo-controlled trial of COVID-19 convalescent plasma in hospitalized patients with early respiratory compromise.

Janoff E, Brown S, Belitskaya-Levy I, Curtis J, Bonomo R, Miller E Contemp Clin Trials Commun. 2023; 35:101190.

PMID: 37560085 PMC: 10407261. DOI: 10.1016/j.conctc.2023.101190.

References

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Bloch E, Shoham S, Casadevall A, Sachais B, Shaz B, Winters J . Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020; 130(6):2757-2765. PMC: 7259988. DOI: 10.1172/JCI138745. View

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004; 24(1):44-6. PMC: 7088355. DOI: 10.1007/s10096-004-1271-9. View

Ackerman M, Das J, Pittala S, Broge T, Linde C, Suscovich T . Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. Nat Med. 2018; 24(10):1590-1598. PMC: 6482471. DOI: 10.1038/s41591-018-0161-0. View

Addetia A, Crawford K, Dingens A, Zhu H, Roychoudhury P, Huang M . Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol. 2020; 58(11). PMC: 7587101. DOI: 10.1128/JCM.02107-20. View

McBride R, Van Zyl M, Fielding B . The coronavirus nucleocapsid is a multifunctional protein. Viruses. 2014; 6(8):2991-3018. PMC: 4147684. DOI: 10.3390/v6082991. View

Pairo-Castineira E, Clohisey S, Klaric L, Bretherick A, Rawlik K, Pasko D . Genetic mechanisms of critical illness in COVID-19. Nature. 2020; 591(7848):92-98. DOI: 10.1038/s41586-020-03065-y. View

Dong E, Du H, Gardner L . An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020; 20(5):533-534. PMC: 7159018. DOI: 10.1016/S1473-3099(20)30120-1. View

Casadevall A, Pirofski L . The convalescent sera option for containing COVID-19. J Clin Invest. 2020; 130(4):1545-1548. PMC: 7108922. DOI: 10.1172/JCI138003. View

10.

Iyer A, Jones F, Nodoushani A, Kelly M, Becker M, Slater D . Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020; 5(52). PMC: 7857394. DOI: 10.1126/sciimmunol.abe0367. View

11.

Merkler A, Parikh N, Mir S, Gupta A, Kamel H, Lin E . Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza. JAMA Neurol. 2020; . PMC: 7333175. DOI: 10.1001/jamaneurol.2020.2730. View

12.

Guo C, Li B, Ma H, Wang X, Cai P, Yu Q . Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat Commun. 2020; 11(1):3924. PMC: 7413381. DOI: 10.1038/s41467-020-17834-w. View

13.

Joyner M, Wright R, Fairweather D, Senefeld J, Bruno K, Klassen S . Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020; 130(9):4791-4797. PMC: 7456238. DOI: 10.1172/JCI140200. View

14.

Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P . Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020; 383(16):1522-1534. PMC: 7315890. DOI: 10.1056/NEJMoa2020283. View

15.

Dieterle M, Haslwanter D, Bortz 3rd R, Wirchnianski A, Lasso G, Vergnolle O . A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. Cell Host Microbe. 2020; 28(3):486-496.e6. PMC: 7332447. DOI: 10.1016/j.chom.2020.06.020. View

16.

Hung I, To K, Lee C, Lee K, Chan K, Yan W . Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52(4):447-56. PMC: 7531589. DOI: 10.1093/cid/ciq106. View

17.

Yoon H, Bartash R, Gendlina I, Rivera J, Nakouzi A, Bortz 3rd R . Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC. JCI Insight. 2021; 6(4). PMC: 7934933. DOI: 10.1172/jci.insight.142270. View

18.

Winkler E, Gilchuk P, Yu J, Bailey A, Chen R, Chong Z . Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021; 184(7):1804-1820.e16. PMC: 7879018. DOI: 10.1016/j.cell.2021.02.026. View

19.

Greaney A, Loes A, Crawford K, Starr T, Malone K, Chu H . Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021; 29(3):463-476.e6. PMC: 7869748. DOI: 10.1016/j.chom.2021.02.003. View

20.

. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021; 397(10289):2049-2059. PMC: 8121538. DOI: 10.1016/S0140-6736(21)00897-7. View